Amylyx Pharmaceuticals recently reported early Phase 1 LUMINA trial data for its ALS candidate AMX0114, showing no treatment-related serious adverse events in the first patient cohort and clearing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback